These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 17062375)

  • 1. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
    Muller N; Schwarz M
    Neurotox Res; 2006 Oct; 10(2):131-48. PubMed ID: 17062375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view.
    Miüller N; Schwarz MJ
    J Neural Transm Suppl; 2007; (72):269-80. PubMed ID: 17982903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunology in schizophrenic disorders].
    Müller N; Schwarz MJ
    Nervenarzt; 2007 Mar; 78(3):253-6, 258-60, 262-3. PubMed ID: 16897051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Des; 2011; 17(2):130-6. PubMed ID: 21361867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 inhibition in schizophrenia and major depression.
    Müller N; Schwarz MJ
    Curr Pharm Des; 2008; 14(14):1452-65. PubMed ID: 18537668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunological treatment options for schizophrenia].
    Müller N; Krause D; Weidinger E; Schwarz M
    Fortschr Neurol Psychiatr; 2014 Apr; 82(4):210-9. PubMed ID: 24710677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological treatment options for schizophrenia.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1606-13. PubMed ID: 22283758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory treatment in schizophrenia.
    Müller N; Myint AM; Krause D; Weidinger E; Schwarz MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr; 42():146-53. PubMed ID: 23178230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
    Müller N
    Curr Opin Investig Drugs; 2010 Jan; 11(1):31-42. PubMed ID: 20047157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.
    Müller N; Schwarz MJ
    Mol Psychiatry; 2007 Nov; 12(11):988-1000. PubMed ID: 17457312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation in schizophrenia.
    Müller N; Myint AM; Schwarz MJ
    Adv Protein Chem Struct Biol; 2012; 88():49-68. PubMed ID: 22814706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
    Myint AM; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
    Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
    Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Mild Stress Alters Kynurenine Pathways Changing the Glutamate Neurotransmission in Frontal Cortex of Rats.
    Martín-Hernández D; Tendilla-Beltrán H; Madrigal JLM; García-Bueno B; Leza JC; Caso JR
    Mol Neurobiol; 2019 Jan; 56(1):490-501. PubMed ID: 29725904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development.
    Müller N
    Expert Opin Ther Targets; 2008 Dec; 12(12):1497-507. PubMed ID: 19007319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia.
    Fujigaki H; Mouri A; Yamamoto Y; Nabeshima T; Saito K
    Neurochem Int; 2019 May; 125():1-6. PubMed ID: 30731185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity.
    Steiner J; Bogerts B; Sarnyai Z; Walter M; Gos T; Bernstein HG; Myint AM
    World J Biol Psychiatry; 2012 Oct; 13(7):482-92. PubMed ID: 21707463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
    Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
    Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes.
    Kepplinger B; Baran H; Kainz A; Ferraz-Leite H; Newcombe J; Kalina P
    Neurosignals; 2005; 14(3):126-35. PubMed ID: 16088227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.